Nevisense currently holds the distinction of being the only FDA-approved AI-driven technology for melanoma detection. By seeking this expanded indication, SciBase intends to transition its diagnostic support tool from a niche melanoma application to a broader clinical instrument capable of assisting dermatologists with the most prevalent forms of skin malignancy. The move aligns the U.S. offering with the company’s existing CE-marked capabilities in Europe.

Chief Executive Officer Pia Renaudin described the submission as a strategic milestone for the firm. She noted that providing objective decision support for a wider array of suspicious lesions is essential to modern dermatological practice, where delayed diagnosis of squamous cell carcinoma can result in metastatic complications. The company will now enter the formal regulatory review process with the FDA to validate the platform's utility for keratinocyte-based assessment.